Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

Buy Advanced Enzyme Technologies; target of Rs 424: Choice Equity Broking

Choice Equity Broking is bullish on Advanced Enzyme Technologies has recommended buy rating on the stock with a target price of Rs 424 in its research report dated April 15, 2021.

April 21, 2021 / 01:06 PM IST
  • bselive
  • nselive
Todays L/H

Choice Equity Broking's report on Advanced Enzyme Technologies

Advanced Enzyme Technologies Ltd. (AETL) is the largest Indian enzyme company and is engaged in the research & development, manufacturing and marketing of 400+ proprietary products developed from over 68 indigenous enzymes and probiotics. The company has manufacturing facilities and research & development centers in India, US and Germany. It exports its products to more than 45 countries across six continents. Revenue for 9M FY21 grew by 10.5% YoY and stood at Rs. 368.6Cr. EBITDA for the period was Rs. 176.6Cr as against Rs. 153.6Cr in the previous year and grew by 15% YoY. PAT grew by 17% YoY and came in at Rs. 114.5Cr. The company works in three segments and provides solutions to a wide variety of industries like human healthcare & nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, leather processing, paper & pulp processing, biofuels, biomass processing and biocatalysis etc.


At current market price of Rs. 355, AETL is trading at a TTM P/E multiple of 27.1x. We value AETL at a P/E multiple of 28x to its FY22 earnings to arrive at a target price of Rs. 424 per share. Thus we assign ‘BUY’ rating to the stock.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Apr 21, 2021 01:06 pm

stay updated

Get Daily News on your Browser